Most material SEC filings — July 9, 2026

As of July 8, 2026, Eightco Holdings (market cap ~$3.8M) disclosed total treasury holdings of approximately $397 million, comprising: $90 million indirect equity in OpenAI (through SPVs), 283.5 million Worldcoin (WLD) tokens valued at $0.39/token (~$110M), 16,278 ETH, $18 million in Beast Industries equity, $1 million in Mythical Games, and $149 million cash/stablecoins. The company holds 8.1% of circulating WLD supply—the largest publicly disclosed institutional position globally. No material changes in holdings were announced; this is a portfolio composition disclosure dated July 8, 2026.

Simply Good Foods reported Q3 FY2026 net loss of $52.0M (vs. $41.1M income YoY) on net sales of $357.0M, down 6.3% YoY, driven by Atkins brand decline of 24.6%. Company recognized $82M impairment charge in Q3 ($331M YTD). Full-year FY2026 guidance cut: net sales expected $1.345–$1.355B (down 7–6% YoY), Adjusted EBITDA $220–$225M (down 21–19% YoY), and gross margins declining ~375 basis points. Q3 Adjusted EBITDA fell 22.5% to $57.2M. Debt increased to $400M as of May 30, 2026 after $150M borrowing in November 2025; Net Debt/Adj. EBITDA ratio 1.2x.

Forte's FB102 (anti-CD122 monoclonal antibody) achieved 29.6% mean FVASI improvement from baseline at week 24 versus 7.9% for placebo (p=0.020) in a 43-subject double-blind Phase 1b vitiligo study (32 FB102, 11 placebo). In the more severely affected subgroup (baseline FVASI ≥0.75), FB102 showed 43.2% mean improvement (p=0.006) with 58.8% achieving FVASI50 responder status. Statistical significance was reached by day 64 and persisted through week 24 post-treatment; 84% of treated subjects improved with 0% worsening, versus 27% of placebo subjects worsening. Safety profile remained mild-to-moderate with no severe adverse events.

MARA Holdings signed a definitive agreement to acquire a 1,200-acre digital infrastructure site in Matagorda County, Texas from HIF USA LLC. The site will provide up to 1 GW of grid capacity by October 2027 and 2 GW by April 2028. HIF retains minority ownership upon execution of an HPC tenant lease. Upon full energization, including the previously announced Long Ridge Energy Power acquisition, MARA's total capacity reaches ~4.8 GW (doubling current portfolio). Phased construction begins 2026; thousands of jobs expected.

Byrna Technologies reported Q2 2026 revenue of $16.4M vs. $28.5M YoY (−43%), driven by weak e-commerce and slower dealer/retail reorders. The company took $10.4M in non-cash charges: $5.9M inventory write-down (ammunition facility shutdown) and $3.5M equipment impairment. It also announced a binding agreement to acquire HERO Defense Systems and initiated cost-reduction actions (cut launcher assembly from 4 to 2 production lines, exited in-house ammunition manufacturing). Cash declined to $10.4M from $15.5M; adjusted EBITDA turned negative at $(0.6)M vs. $4.3M prior year. Management flagged fiscal 2026 will not be a growth year.

Element Solutions Inc agreed to merge with Solstice Advanced Materials Inc (Parent) in a two-step transaction dated July 6, 2026. Each Element Solutions share converts to 0.500 Parent shares plus $10.00 cash. As of July 1, 2026, Element Solutions had 243.7M shares outstanding; Parent had 158.8M shares outstanding. The transaction contemplates Parent issuing shares for the merger consideration and Parent obtaining debt financing. Designated Company directors will join Parent's board post-closing.

Solstice Advanced Materials Inc. (Parent) agreed to acquire Element Solutions Inc. (Company) via merger as of July 6, 2026. Element shareholders receive 0.50 Solstice shares plus $10.00 cash per share. Solstice will issue approximately 121.8M new shares (243.7M Company shares × 0.50 Exchange Ratio). Deal requires majority votes from both companies' shareholders and regulatory approvals; expected to close in H2 2026.

MetaVia announced July 9, 2026 that all enrolled patients in Phase 1 Part 3 of DA-1726 (dual GLP-1/glucagon agonist) successfully reached target doses of 48 mg (Part 3A, ~20 patients) and 64 mg (Part 3B, ~20 patients) across two 16-week titration cohorts. Topline data expected Q4 2026. Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks with improved waist circumference and glycemic measures.

Splash Beverage Group announced on July 8, 2026 that NYSE American accepted its compliance plan and granted a compliance period through January 29, 2027, after the company submitted the plan on May 29, 2026. The company stated it has secured an equity line facility for liquidity, completed a strategic investment in Avicanna, and acquired exclusive worldwide licensing rights to CannEpil. The filing does not specify dollar amounts for the equity facility, the Avicanna investment, or the CannEpil acquisition price.

Stereotaxis completed its acquisition of Robocath, a France-based developer of robotic solutions for interventional cardiology and neurointerventions, as of July 9, 2026. The filing does not disclose the purchase price, share count exchanged, or other financial terms. Robocath's R-One robotic platform has CE and NMPA certifications and is currently deployed in Europe and China; the combined entity aims to expand robotic offerings across electrophysiology, interventional cardiology, and neurointerventions.

Ampco-Pittsburgh announced customer order activity of $268 million for H1 2026, up 32% from $204 million in H1 2025. FCEP segment orders grew 25% to $153 million; Air and Liquid Processing grew 42% to $116 million. Growth driven by roll products in North America, Navy pump programs, and Buffalo Air Handling's largest-ever order.